Other languages Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.13 ^USD	-7.39%		-17.12%	-69.22%

Apr. 18	Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	MT
Apr. 18	Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	Apr. 18
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	Mar. 20
Immix Biopharma Proposes Stock Offering; Shares Slump	Feb. 05
Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1	Dec. 11
Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis	Nov. 22
GNW-Adhoc: Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht	Nov. 22
La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains	Nov. 22
Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht	Nov. 22
Immix Biopharma Says FDA Clears Investigational New Drug Application for NXC-201; Shares Fall	Nov. 21
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients	Nov. 06
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site	23-10-16
Immix Biopharma, Inc. Announces Complete Response in 9Th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial At IMS 20Th Annual Meeting	23-10-03
Top Midday Gainers	23-10-02
Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma	23-10-02
Immix Biopharma Files Registration Statement on Behalf of Selling Stockholder	23-09-26
Immix Biopharma Gets FDA Orphan Drug Label For NXC-201 to Treat Amyloid Light Chain Amyloidosis	23-09-21
Sector Update: Health Care Stocks Rising Late Afternoon	23-08-23
Sector Update: Health Care	23-08-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Other languages

Filters